Interestingly, one of these two compounds, TZD, is a well-established agonist of the peroxisome proliferator activated receptor gamma (PPARγ), a target that has been previously studied as a potential therapy for various neurodegenerative diseases including HD, confirming the usefulness of our screen to identify potential therapies.26 The gene discussed is PPARG; the disease is Huntington disease.